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1. Introduction
In the 1940’s, the development of penicillin as a potent broad-range antibiotic revolutionized
the treatment of infectious disease and ushered in a prolific discovery period of natural
small molecules produced by microorganisms that were antagonistic towards the growth of
other bacteria. Antibiotics have generally been classified by their mechanism of action. For
example, the β-lactam compounds, penicillin and cephalosporins, disrupt the synthesis of
the peptidoglycan layer of the bacterial cell wall, whereas protein synthesis inhibitors, such
as tetracycline and some aminoglycosides, bind to the 30S ribosomal subunit and block ad‐
dition of amino acids to the growing peptide chain. By the 1960’s, the majority of all antibi‐
otics in use today had been isolated and developed for public consumption, leading the U.S.
Surgeon General to declare in 1968 that the war on infectious disease had been won.
Unfortunately, nature has found a way to thwart mankind’s effort to contain infectious dis‐
ease. Under the selective pressure of antibiotics that target different cell processes, bacteria
have evolved to become resistant to the lethal effects of many classes of antibiotics. One
stark example that has emerged as a major public health threat is methicillin-resistant Staph‐
ylococcus aureus (MRSA), which is estimated to cause ~19,000 deaths in the US annually [1].
MRSA has become resistant to β-lactam antibiotics by acquiring the resistance gene mecA,
which encodes for a unique penicillin binding protein PBP2A that can function as a surro‐
gate for native staphylococcal PBPs normally inactivated by β-lactam antibiotics. In the last
decades of the 20th century, MRSA has continued to evolve in response to a continually
changing human environment, from a primary agent of hospital-acquired infections to a
multi-drug resistant strain that has also acquired Tn1546 transposon-based vancomycin re‐
sistance. Furthermore, the appearance of MRSA strains in a community setting may be a
stepping stone to the evolution of a completely drug-resistant strain.
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There is no question that new strategies that target different aspects of pathogen function
are urgently needed to combat multi-drug resistant bacteria. However, very few new scaf‐
folds for drug discovery developed after the 1960s have been found to be effective [2]. To
date, only four new classes of antibiotics, including mutilins and lipopeptides, have been in‐
troduced, but none of these have proven to be as effective as the panel of classic antibiotics.
Instead, established scaffolds have been modified or re-purposed to develop successive gen‐
erations of effective antibiotics. For example, the core structure of cephalosporins have been
left intact to preserve activity, but the peripheral chemical groups have been modified to im‐
part the molecule with the ability to penetrate the bacterial membrane more efficiently or be
more resistant to β-lactamase [3]. Modifications of four classic antibiotics, cephalosporin,
penicillin, quinolone, and macrolide, account for ~73% of the “new” antibiotics filed be‐
tween 1981 and 2005 [4]. It is also important to note that small compounds need to exhibit
not only anti-microbial activity, but also minimized cytotoxic properties to widen their ther‐
apeutic window.
Although advances in organic synthesis have extended the lifetime of classic antibiotics
through synthetic modifications, new scaffolds are also needed. Recent efforts to search for
new modalities amongst previously-overlooked natural sources, such as unmined bacterial
taxa and ecological niches, have started to bear fruit. The increasingly rapid data acquisition
and low cost of ultra high-throughput sequencing has provided rich coverage of bacterial
genomes and transcriptomes. For example, genomic analyses of a vancomycin-resistant
strain of Amycolatopsis orientalis revealed the presence of genetic loci that encode for at least
10 other secondary metabolites. One compound, ECO-0501, exhibited strong anti-bacterial
properties against Gram-positive pathogens, including several strains of MRSA [5]. Mass
spectroscopy (MS) is another primary methodology used to identify small molecule metabo‐
lites with potential anti-microbial properties. The polycyclic small molecule, abyssomicin C,
from the marine actinomycete Verrucosispora was characterized as an inhibitor of p-amino‐
benzoate biosynthesis by MS and also exhibited antimicrobial properties against MRSA
strains [6].
2. Methodology for high-throughput screens (HTS) using small molecule
libraries
The workhorse platform for anti-bacterial drug discovery is a chemical genetics HTS ap‐
proach using small molecule compound libraries to identify candidates that inhibit bacterial
growth or the function of key bacterial enzymes. Small molecules, generally <500 molecular
weight, have the potential to enter cells and selectively perturb specific protein activity, thus
functioning as therapeutic agents against disease. In general, the precise mechanism of in‐
hibitor activity remains unknown in the initial screen. Subsequent identification of the mo‐
lecular targets of small molecules will have to be performed to implicate the specific
bacterial functions that were inactivated in the screen. Thus, HTS can sample a large un‐
biased collection of structurally diverse molecules to select compounds that perturb the de‐
fined cell phenotype of interest. (Fig. 1)
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Various chemical compound libraries are now available through commercial and public re‐
sources that include FDA-approved bioactive compounds, therapeutic agents, and natural
products. To maximize the structural complexity and diversity of small molecule libraries,
scientists have also employed diversity-oriented synthesis,
Figure 1. General flowchart of high-throughput methodology to screen small molecule libraries for inhibitors of host-
pathogen interactions
in which different scaffolds are modified with highly diverse functional groups. [7, 8]. To
bolster academic research in chemical biology efforts for HTS-driven identification of bioac‐
tive compounds, the NIH launched the Molecular Libraries Program in 2005 to offer ac‐
cess to ten large-scale automated HTS centers in the Molecular Libraries Probe Production
Centers Network, including diverse compound libraries through the Small Molecule Repo‐
sitory and information on biological activities of small molecules in the PubChem BioAs‐
say public database.
A variety of different molecular and cellular methods have been developed for HTS using
small molecule libraries. Automated microscopy has been utilized for high-content, image-
based screens of cells exposed to small molecules. Acquired cell images can be analyzed by
automated image analysis software to quantitate physiological changes at the single-cell lev‐
el, including phenotypes such as morphology and cell toxicity. Small molecule microarrays,
in which ~10,000 small molecules are covalently bound to a glass slide, has been generated
to detect high affinity binding to a protein of interest, as a potential inhibitor of function.
Binding of the protein of interest to specific compounds on the microarray was then detect‐
ed with fluorescent antibodies [9].
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3. Disruption of host-pathogen interactions for novel drug discovery
Given the innovation gap in the discovery of novel antibiotics post-1960, strategies to inhibit
novel targets are greatly needed to combat infectious disease. Multiple studies have identi‐
fied small molecule inhibitors that target gene expression of pathogen TTSS components in
P. aeruginosa, enteropathogenic E. coli, and Y. pestis [10, 11, 12]. The small molecule virstatin,
4-[N1,8-naphthalimide)]-n-butyric acid, was identified as an inhibitor of the transcriptional
regulator ToxT in Vibrio cholerae [13]. The small molecule, 2-imino-5-arylidene thiazolidi‐
none, which blocks TTSS-dependent functions in S. typhimurium, was also found to inhibit
virulence in Yersinia, Pseudomonas, and Francisella strains, indicating that compounds can be
identified that target common processes in multiple pathogens [14].
Research efforts have recently begun to focus on disruption of host-pathogen interactions as
a new approach to identify potential targets for drug discovery, rather than solely on specif‐
ic pathogen targets or processes. In particular, the screening of small molecule libraries to
identify inhibitors that block pathogen infection of the host, using such phenotypes as
pathogen invasion, host morphology, and pathogen replication in the host, is a powerful ap‐
proach for therapeutic development that may uncover fundamental mechanisms of patho‐
genesis and potentially lead to discovery of new classes of anti-infective agents. Here, we
describe case studies of the use of small molecules in host infection screens to identify novel
inhibitors against infectious disease, including bacterial, viral, parasitic, and fungal infec‐
tions. We will discuss these studies in the context of re-purposing known drugs, inhibitor
specificity, and discovery of basic mechanisms of host-pathogen interactions. The screen re‐
sults are summarized in Table 1.
Screening for inhibitors of intracellular infection
Intracellular pathogens, including viruses, parasites, and some bacteria, manipulate specific
host factors in order to downregulate the host immune response or modulate host actin cy‐
toskeleton rearrangements to induce phagocytic uptake of the pathogen. L. monocytogenes,
an intracellular Gram-positive bacteria, infects the human host primarily through ingestion
of contaminated foods and causes gastrointestinal infection. In 2011, Listeria contamination
of cantaloupes led to at least 30 deaths and ~150 illnesses in 28 states. Following internaliza‐
tion of L. monocytogenes in host membrane-bound vacuoles, the pore-forming cytolysin, lis‐
teriolysin O (LLO) and a phosphatidylinositol-specific phospholipase C (PI-PLC) mediates
lysis of the vacuoles to release the pathogen into the host cell cytosol. L. monocytogenes then
polymerizes host actin to propel itself into adjacent host cells to continue the infection proc‐
ess. To identify compounds that inhibited L. monocytogenes intracellular infection, a screen of
480 small molecules from the Biomol ICCB Known Bioactives library was performed using
automated microscopy and image analysis [15]. Murine bone marrow-derived macrophages
were infected with a GFP-expressing L. monocytogenes strain to assess efficiency of invasion,
survival, and replication in the host. Twenty-one compounds, affecting cell functions such
as actin polymerization, calcium signaling, and apoptosis, were identified that markedly de‐
creased Listeria monocytogenes infection efficiency. In particular, the FDA-approved anti-psy‐
chotic drug pimozide, used to treat Tourette’s syndrome and schizophrenia, was shown to
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decrease internalization of not just L. monocytogenes, but other bacterial species as well, in‐
cluding Bacillus subtilis, Salmonella typhimurium, and E. coli. Furthermore, pimozide de‐
creased vacuole escape and cell-to-cell spread of L. monocytogenes in the host. Thus,
pimozide is an example of a small molecule that can be re-purposed to treat infectious dis‐
ease with potential for broad spectrum anti-microbial applications.
Parasites also employ a life cycle of host cell invasion, replication, and host cell lysis during
onset of infection. Taxoplasma gondii is the protozoan intracellular human parasite of the
phylum Apicomplexa and is related to Plasmodium and Cryptosporidium, the causative agents
of malaria and diarrheal disease, respectively. To discover inhibitors of T. gondii invasion, a
high-throughput
Table 1 Small molecule screens using host-pathogen systems
microscopy assay was developed to distinguish between extracellular and intracellular para‐
sites in a BS-C-1 epithelial cell model, using differential labeling with fluorescent dyes [16]. Out
of a 12,160 structurally-diverse small molecule library, 24 non-cytotoxic inhibitors were identi‐
fied that reduced parasite invasion to <20% compared to control wells. These molecules inhib‐
ited different aspects of the infection process, including gliding motility and secretion of host
cell adhesins. One of these inhibitors, tachypleginA, was found to post-translationally modify
TgMLC1, a myosin light chain component of the T. gondii myosin motor complex, which drives
host cell penetration and parasite mobility [17]. TgMLC1 exposed to the small molecule exhib‐
ited a rapid and irreversible change in electrophoretic mobility on SDS-PAGE gels. Although
the exact nature of the modification remains unclear, the modification has been mapped to
amino acids V46-R59 by mass spectroscopy. These studies provide key mechanistic informa‐
tion on the importance of T. gondii motility in pathogenesis and illustrate the potential for small
molecules to form covalent interactions with target proteins.
Targeting virulence toxin mechanisms of infection
Many Gram-negative bacteria, including Pseudomonas and Yersinia, utilize the TTSS as a pri‐
mary mechanism of virulence to inject effector proteins into the host cytosol to downregu‐
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late the host immune response. A host cytotoxicity assay was designed to screen for small
molecule inhibitors of Pseudomonas aeruginosa, a leading cause of hospital-acquired infec‐
tions in cystic fibrosis patients. P. aeruginosa ExoU, a TTSS effector protein, is a member of
the patatin family of phospholipase A2 (PLA2) that can lyse host cell membranes during in‐
fection. A high-throughput screen of 50,000 compounds from the Chembridge Microformat
Library E was performed using a colorimetric live/dead assay to identify small molecules
that protected Chinese hamster ovary (CHO) cells from cytotoxicity mediated by P. aerugino‐
sa expressing ExoU as the sole TTSS effector [18]. A primary list of 88 compounds exhibited
rescue of CHO cells from ExoU-mediated cytotoxicity. The most effective compound, pseu‐
dolipasin A, inhibited ExoU function downstream of TTSS delivery into the host. In addition
to inhibition of CHO cytotoxicity, pseudolipasin A also protected the amoeba Dictyolstelium
discoideum from ExoU-mediated killing by P. aeruginosa and inhibited cytotoxicity in the
yeast Saccharomyces cerevisiae expressing ExoU. Interestingly, pseudolipasin A did not affect
eukaryotic PLA2, suggesting that this small molecule may specifically target bacterial PLA2.
Pseudolipasin A is representative of small molecules that do not kill or inhibit the growth of
pathogens, but instead attenuate their virulence.
Inhibitors of P. aeruginosa virulence have also been identified using a cell-based yeast pheno‐
typic assay in combination with a large-scale small molecule screen. A total of 505 P. aerugi‐
nosa virulence factors and essential genes were individually overexpressed in S. cerevisae to
downselect genes that inhibited yeast growth [19]. Nine genes strongly or partially impaired
yeast growth, including three TTSS effectors, ExoS, ExoT, and ExoY. ExoS has been previ‐
ously shown to ADP-ribosylate multiple downstream targets, including vimentin, the Ras
family of small GTP-binding proteins, and cyclophilin A. Given that ExoS is a critical media‐
tor of P. aeruginosa chronic infections, a library of 56,280 compounds was screened to find
inhibitors of ExoS ADP-ribosylation activity that rescued cytotoxicity in yeast. Six com‐
pounds were identified that restored yeast growth. The most promising compound, exosin,
was found to modulate ExoS enzymatic activity in vitro and exhibited a protective effect
against P. aeruginosa infection in mammalian CHO cells. This study demonstrates the effec‐
tive use of a simple eukaryotic host, baker’s yeast, as a tool for drug screening for applica‐
tions in controlling infectious disease in humans.
Another pathogen family that employs the TTSS is Yersinia, which secrete Yop effectors into
the host cell. There are three Yersinia human pathogens, Y. pestis, the etiological agent of pla‐
gue via intradermal fleabites or inhalation, and Y. pseudotuberculosis and Y. enterocolitica,
which cause mild and self-limiting enteric disease by the oral route. HTS strategies have
been developed to identify small molecules that inhibit translocation of the Yops into host
cells. A recombinant Y. pseudotuberculosis strain was constructed to express a chimeric pro‐
tein containing the first 100 amino acids of YopE, which contains the proper translocation
signals to inject into the host, fused to a fragment of β-lactamase. [20]. This bacterial strain
was used to infect HEp-2 host cells treated with a non-membrane-permeating, non-fluores‐
cent dye CCF2-AM, which fluoresces green at 520nm, as a result of intramolecular FRET be‐
tween the 7-hydroxycoumarin and fluorescein molecules, conjugated by a lactam ring. Upon
cellular uptake, CCF2-AM is modified by cytoplasmic esterases and is trapped in the host
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cell. If the YopE-β-lactamase fusion is introduced into the host, the β-lactamase will cleave
the lactam ring in CCF2-AM and liberate the fluorescein, leaving the coumarin to fluoresce
blue at 447nm. Using this differential fluorescence assay, 100,000 compounds from a number
of sources, including the ChemDiv 2, ChemDiv 3, ChemDiv 4, Maybridge 3, Maybridge 4,
and Biomol ICCB libraries, were screened for low ratios of blue-to-green fluorescence. In to‐
tal, 200 compounds were deemed potential hits, and 45 were assessed further using secon‐
dary assays, including rounded host morphology in response to Yersinia infection. Finally, 6
compounds were found that inhibited translocation of effectors into the host without affect‐
ing expression and function of TTSS components. Several of these compounds also inhibited
host cell rounding when induced by Pseudomonas effectors, suggesting that these com‐
pounds may have a broad-spectrum anti-infective effect.
A screen to identify small molecule inhibitors of B. anthracis also employed the CCF2-AM
FRET assay. B. anthracis, the Gram-positive causative agent of anthrax, secretes three major
toxins during infection, lethal factor (LF), protective antigen (PA), and edema factor (EF). A
fusion protein between LF and β-lactamase was introduced into host cells by PA-directed
endocytosis to hydrolyze the CCF2-AM fluorogenic substrate [21]. Out of 70,094 compounds
tested, 1170 initial hits exhibited concentration-dependent inhibition of β-lactamase activity.
Thirty compounds with known biological activities and/or were high confidence hits were
selected for further analysis. Three compounds, NCGC00084148-01, diphyllin, and niclosa‐
mide, exhibited protective effects from anthrax LF, a LF fusion to Pseudomonas exotoxin, and
diphtheria toxin in RAW264.7 murine macrophages and CHO cells, and are thought to inter‐
fere with toxin internalization in the host.
The interaction between B. anthracis EF and its cellular activator, calmodulin (CaM), became
the basis of a two-step tandem screen to identify small molecule inhibitors of anthrax infec‐
tion. A library of 10,000 compounds (Chembridge, Library # ET350-1) in pools of 8 was
screened to identify small molecules that blocked an EF-induced flat to round morphology
change in Y1 murine adrenocortical cells [22]. Twenty-four initial hits were then individual‐
ly tested using surface plasmon resonance (SPR) to identify molecules that block interactions
between EF and immobilized CaM. One compound, (4-[4-(3,4-cichlorophenyl)-thiazolylami‐
no]-benzenesulfonamide) 10506-2A, efficiently inhibited EF-CaM binding in a dose-depend‐
ent manner, and was found to specifically target the CaM binding region of EF by
fluorescence spectroscopy. Since this compound was found to be toxic in cultured mammali‐
an cells, a series of structurally-related compounds was synthesized, and a new inhibitory
compound with reduced toxicity was subsequently identified.
Small molecule discovery in plant-pathogen interactions
Discovery of small molecule inhibitors has also been extended to plant pathogen systems as
an approach to develop commercially-relevant chemicals to protect crops assets from dis‐
ease. The Gram-negative pathogen Pseudomonas syringae expresses a TTSS, enters plant tis‐
sues through the stomata or wounds, and infects a wide range of plant species. A major
challenge in the application of small molecule screens to plant-pathogen interactions is the
development of high-throughput methodology with a plant model system. A high-through‐
put liquid assay was developed based on P. syringae-induced bleaching of Arabidopsis thali‐
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ana cotyledon seedlings, which signifies a loss of chlorophyll from plant tissues and is
indicative of bacterial pathogenesis [23]. A screen of ~200 small molecules active in Arabidop‐
sis (LATCA, Library of Active Compounds in Arabidopsis) identified several sulfanilamide
compounds, including sulfamethoxazole, sulfadiazine, and sulfapyridine, that prevented co‐
tyledon bleaching upon P. syringae infection. The most potent compound, sulfamethoxazole,
also inhibited P. syringae growth in mature soil-grown plants. A similar assay was used to
implicate the same compound, sulfamethoxazole, and the indole alkaloid gramine as inhibi‐
tors of Fusarium graminearum fungal infection in Arabidopsis and wheat, indicating that this
strategy represents a relevant surrogate system for identification of compounds that can pre‐
vent agriculturally-important infectious disease [24].
Combinational antiviral therapies for HIV
Given that viral pathogens are absolutely dependent on the host for propagation, even more
so than bacterial pathogens, research in host-directed anti-virals has advanced at a faster
pace than that for anti-bacterial agents. Human Immunodeficiency virus type 1 (HIV-1), a
lentivirus of the retroviral family and the causative agent of AIDS, is the most-widely stud‐
ied viral pathogen to date. HIV-1 infection causes a dramatic decline in host CD4+ T cell
numbers and a progressive failure of the immune response, which makes the host suscepti‐
ble to opportunistic infections and cancer. The highly glycosylated HIV-1 envelope, in com‐
bination with the extreme diversity of circulating viral strains, have presented daunting
challenges for development of an effective vaccine. Furthermore, the virus establishes chron‐
ic infection that resists the highly active antiretroviral therapy (HAART). Conventional
HAART for HIV-1 infection combines three main classes of anti-viral drugs:
1. nucleoside reverse transcriptase inhibitors (NRTIs),
2. non-nucleoside RT inhibitors (NNRTIs), which target the non-catalytic domain of RT,
and
3. protease inhibitors (PIs).
HAART is usually patient-specific, and its formulation is determined by the viral load and
drug resistance. A traditional HAART consists of two NRTIs and a NNRTI or a PI [25]. More
advanced combination therapies include a fourth class of antiretroviral drugs, HIV entry in‐
hibitors. HIV-1 entry into human cells is dependent on several sequential steps that include
binding of viral envelope protein gp120 to the CD4 receptor, and conformational change in
gp120 that increases its affinity to the chemokine co-receptors (CCR5 or CXCR4) and expos‐
es gp41, an HIV envelope protein that executes the fusion of HIV and host cell membranes.
Currently, there are two approved inhibitors of HIV-1 entry:
1. enfuvirtide, a peptide fusion inhibitor that binds to gp41 and
2. maraviroc, a small molecule entry inhibitor that prevents interaction between gp120
and CCR5.
The β-chemokine receptor CCR5 was found to act as a major co-receptor for the macro‐
phage-tropic HIV-1 R5 strains, predominant in the early asymptomatic stages of virus infec‐
Drug Discovery164
tion, whereas the T-cell-tropic strains (using the CXCR4 co-receptor) become prevalent in
the symptomatic stages concomitant with the decline of CD4+ T-cells [26]. CCR5 is an attrac‐
tive target for development of HIV-1 entry inhibitors, given the discovery that HIV-1 non-
progressors, individuals homozygous for a 32-bp deletion in the coding region of CCR5
gene (CCR5Δ32) were naturally resistant to infection with R5 HIV-1 [27]. Natural and syn‐
thetic CCR5 ligands such as RANTES, AOP-RANTES, Mip-1α, Mip-1β,and Met-RANTES
were found to efficiently protect against R5 HIV-1 infection [28, 29]. Thus, the first published
high throughput screen (HTS) for discovery of non- peptide inhibitors of HIV-1 entry was
performed in a virus-free cell-based system using [125I]-labeled RANTES. A strong inhibitor
of RANTES binding to CCR5 stably expressed on the surface of CHO cells was identified
from the library of Takeda Chemical Industries. Further chemical modifications of the lead
compound designated TAK-779 produced a potent (IC50 1.4 nM in CHO/CCR cells) and se‐
lective CCR5 antagonist capable of blocking R5 HIV-1 infection in vitro [30].
The number of CCR5 inhibitors has significantly grown since the discovery of TAK-779, but
very few compounds have entered clinical trials, and only maraviroc has been approved for
clinical use [31]. A radiolabeled-chemokine binding assay similar to one applied for the
identification of TAK-779 was used in a HTS of a small molecule library at Pfizer for the dis‐
covery of UK-107,543, which had become a scaffold for intensive medicinal chemistry, pro‐
ducing ~1,000 analog compounds, from which maraviroc (UK-427,857) was selected for its
excellent preclinical pharmacokinetics (90% inhibitory concentration of 2 nM in pool of
PBMCs from various donors) [32]. Despite its proven efficacy against HIV-1 R5 infection,
maraviroc is vulnerable to gp120 escape mutations [33]. Site-directed mutagenesis and mo‐
lecular modeling studies have identified a common binding pocket on CCR5 that is shared
by various small-molecule CCR5 inhibitors [34, 35, 36]. Emerging details on gp120 and
CCR5 points of interaction and binding thermodynamics provide valuable information that
can be applied in developing tools for rational design of novel HIV-1 entry inhibitors [37,
38]. Efficient block of HIV entry into host cells is essential to curtail virus dissemination and
is a key step towards eradication of HIV infection. The current HAART regiment can reduce
HIV replication to very low levels (below 50 copies/ml plasma) and can lead to recovery of
CD4+ T-cell counts but not cure the infection. Patients that have been successfully treated
with HAART for years have experienced a rapid virus rebound upon termination of the
therapeutic regiment [39, 40]. Such clinical cases present evidence that HIV establishes a
chronic infection that resists current HAART designed to target actively replicating virus. A
deliberate and controllable induction of HIV-1 replication from its latent reservoirs in com‐
bination with HAART is a novel and actively pursued approach that aims to eliminate both
active and latent viral pools [41].
Researchers often seek new anti-infective agents amongst small molecules that have previ‐
ously been approved for the treatment of cancer and neurological diseases, since they have
well-established pharmacokinetics and in most cases, known molecular mechanisms of ac‐
tion. One example of this is the histone deacetylase (HDAC) inhibitor, valproic acid (VA),
which had previously been approved for treatment of neurological and psychiatric disor‐
ders. HIV-1 has been shown to enter dormancy using epigenetic silencing via deaceylation
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of histones in the vicinity of the integrated viral genome [42]. Thus, VA was tested as a po‐
tential agent to disrupt HIV-1 latent infection. However, years of VA treatment in combina‐
tion with HAART showed no clearance of the latent HIV reservoir [43]. A more potent
HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), approved for treatment of cuta‐
neous T-cell lymphoma, was subsequently tested as a potential agent that could ‘flush out’
HIV-1 from latently infected cells, based on its superior effect to VA in cell culture models
[44, 45]. A substantial effort has also been invested in the design and synthesis of bryostatin
chemical analogs, small molecules that activate protein kinase C (PKC) with single nanomo‐
lar concentration [46]. PKC activation leads to phosphorylation of nuclear factor κB (NFκB),
a key transcription factor regulator of HIV-1 gene expression [47]. However, modulation of
NFκB activity requires great caution, since abnormal NFκB signaling has been related to the
pathophysiology of inflammatory diseases and neurodegenerative disorders [48].
A HTS of a small molecule library recently identified novel HIV latency activators [49]. The
screen was performed using a lymphoma CD4+ T-cell line (SupT1) harboring latent recombi‐
nant HIV-1 and two reporters that reflect early and late virus gene expression incorporated
in the HIV-1 genome [50]. A luminescent assay based on secreted alkaline phosphatase
(SEAP) activity, incorporated in the late virus gene transcripts, was applied to screen a
chemical library of ~200,000 compounds. Validation of 27 hits with diverse chemical struc‐
tures demonstrated induction of latent virus from various cell models. Compounds with a
selective index (CC50/EC50) above 25 were chosen for downstream medicinal chemistry mod‐
ifications. Moreover, the lead compounds were shown to reactivate latent HIV from primary
resting CD4+ T-cells with no induction of cell proliferation. Small molecule activators of la‐
tent HIV that act in concert using different mechanisms have a better chance of purging the
virus out of infected cells [49]. Such pre-clinical data strongly suggests that successful treat‐
ment of HIV infection can be achieved only through combinational therapy consisting of di‐
verse class of antiviral drugs.
4. Whole animal small molecule screens using C. elegans
In vitro high-throughput screens have several limitations for the discovery of therapeutic in‐
hibitors with high efficacy. Synthetic compound libraries often contain toxic compounds
with poor pharmacokinetic properties, and many in vitro assays are not physiologically-rele‐
vant in the context of which a specific drug is expected to function. In a previous section, we
had described the use of a HTS whole organism-based assay based on Arabidopsis seedlings
as the host system. Here, we detail the use of a whole animal model, the nematode worm C.
elegans, in chemical screens that permit simultaneous assessment of the immunomodulatory
effects, potential toxicity of compounds, and drug efficacy in a host with a functioning im‐
mune system. The results of these screens are summarized in Table 2. Whole animal screens
have the distinct advantage of being able to directly discard compounds that induce organ‐
ismal toxicity and can identify compounds that target host-pathogen interactions in a rele‐
vant physiological context.
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C. elegans, a hermaphroditic nematode normally found in soil, is a versatile, more ethically-
acceptable whole animal system for high-throughput analysis of host response to pathogen
infection. C. elegans contains a fully sequenced genome that facilitates both genetic and ge‐
nomic analysis, offering an ideal compromise between organismal complexity and experi‐
mental tractability. C. elegans offers other experimental advantages, including a rapid 2-3
week life span, simple growth conditions, target-selected gene inactivation, and a relatively
low cost of maintenance compared to other whole animal systems. A wealth of experimental
data has demonstrated that many developmental, neurological, and biochemical processes
have been highly conserved between C. elegans and mammals. For example, cellular func‐
tions as diverse as innate immunity, the first line of defense against pathogen infection, and
RNA interference to downregulate gene expression via double-stranded RNA, are found in
both C. elegans and higher eukaryotes, suggesting the existence of a common ancestor of
these diverse species. Thus, anti-infective compounds identified using a C. elegans infection
model may also be translatable in humans.
C. elegans as a model host system has been well-studied for numerous bacterial pathogens, in‐
cluding the Gram-positive S. aureus, S. pneumoniae, and B. thuringiensis, and the Gram-nega‐
tive B. pseudomallei, P. aeruginosa, and S. marcescens. In general, different types of bacteria are
fed to C. elegans in place of their normal E. coli food source to provoke detectable symptoms of
illness, such as locomotion dysregulation, intestinal cell lysis, and shortened life span.
Small molecule inhibitors of bacterial infection
A small manual screen of 6000 synthetic compounds and 1136 natural extracts were ana‐
lyzed in an immunocompromised mutant of C. elegans infected with Enterococcus faecalis to
identify compounds that promoted host survival. [51]. A total of 16 compounds and 9 ex‐
tracts were identified that either modulated bacterial growth in vitro, impaired pathogen vir‐
ulence, or boosted host innate immunity. Furthermore, 15 out the 16 compounds did not kill
C. elegans or mammalian erythrocytes, indicating that the compounds are not toxic.
The development of automated sorting and handling of C. elegans rapidly enabled high-
throughput screening of small chemical libraries to identify compounds that enhanced sur‐
vival of C. elegans in response to bacterial infection. This methodology was enabled by the
Complex Object Parametric Analyzer and Sorter (COPAS) BioSort worm sorter (Union Bio‐
metrica) to dispense a defined number of living worms into multi-well plates, which were
then imaged using automated microscopy to quantify worm survival. A library of 37,200
compounds and natural product extracts was screened using the same C. elegans-E. faecalis
infection system described above [52]. Twenty-eight compounds and extracts were identi‐
fied that enhanced survival of infected C. elegans. Six structural classes of identified com‐
pounds did not affect the growth of E. faecalis itself, suggesting that the small molecules
inhibited a specific aspect of the host-pathogen interaction. Interestingly, two structural
classes are similar to compounds previously identified in a high-throughput screen to iden‐
tify inhibitors of P. aeruginosa biofilm development, indicating the presence of common mo‐
lecular targets across multiple bacterial species for drug discovery [53].
A P. aeruginosa infection model of C. elegans has also been developed to screen for novel anti-
infective compounds. The high-throughput assay was based on P. aeruginosa-induced slow
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killing of C. elegans in the presence of 1300 bioactive extracts produced by endophytic fungi
associated with medicinal plants [54]. The screen identified 36 extracts that promoted the
survival of the infected worms, while 4 extracts were found to inhibit P. aeruginosa growth
using a disc diffusion assay. Given that these extracts contain a mixture of metabolites, the
specific compound against P. aeruginosa remains to be determined. Nevertheless, this study
illustrates the rich reservoir of small molecules in natural symbiotic organisms with anti-
bacterial activity.
Table 2 Small molecule screens using C. elegans as host model for infection
Discovery of novel antifungal agents
The C. elegans infection model was also used to screen for compounds that prolonged host
survival following infection with the human pathogenic fungus Candida albicans. [55]. Given
that most compounds that have antifungal activity are also toxic to the human host, high-
throughput methods can greatly increase the likelihood of discovering specific antifungal
inhibitors. From a screen of 1266 compounds with known pharmaceutical activities, 15 small
molecules were identified that increased survival of C. albicans-infected nematodes and in‐
hibited in vivo filamentation of C. albicans, a mechanism of pathogenesis seen during mam‐
malian infection. Two compounds, caffeic acid phenethyl ester (CAPE), a natural
component of honeybee propolis, and the fluoroquinolone agent enoxacin, were further
shown to exhibit antifungal activity in a mouse model, validating the use of a C. elegans
model for potential targets in a mammalian system. Interestingly, CAPE is known to inhibit
the mammalian transcription factor NF-κΒ and to induce immunomodulatory effects in
mice [56, 57]. Since C. elegans does not express a NF-κΒ homolog, it may be the case that
CAPE affects alternative targets to achieve antifungal activity.
An automated high-throughput screen using the COPAS Biosort was also applied to C. albi‐
cans infection of C. elegans to assess a library of 3,228 compounds consisting of 1948 bioactive
compounds and 1280 small molecules derived from diversity-oriented synthesis [58]. In to‐
tal, 19 compounds were identified that increased C. elegans survival in response to C. albicans
infection, 7 of which are currently used antifungal agents. Several immunosuppressant
agents identified in this screen, including ascomycin, cyclosporin A, and FK-506, were previ‐
ously found to exhibit weak antifungal activity against Cryptococcus and Aspergillus, in addi‐
tion to C. albicans [59, 60]. Other hits were predicted to affect an array of biological activities,
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such as dequalinium chloride, a potent anti-tumor and protein kinase C inhibitor, and tria‐
dimefon, an inhibitor of ergosterol biosynthesis.
5. Conclusion
Chemical library screens are a potent and valuable molecular tool for HTS identification of
potential inhibitors of infectious disease. The long-standing paradigm to treat pathogen in‐
fection with small molecules that specifically target pathogen growth or metabolism has led
to our current dilemma of microbial drug resistance and re-emergence of once-contained in‐
fectious diseases. Thus, new approaches to target pathogen virulence or host response fac‐
tors rather than essential pathogen functions have become increasingly more attractive
strategies that are less likely to induce microbial resistance. Some compounds, such as the
FDA-approved anti-psychotic, pimozide, exhibited inhibitory properties against infection by
several pathogens, suggesting that small molecules can potentially be developed as broad-
spectrum anti-infectives. Although the molecular mechanism of inhibition by small mole‐
cules remains unknown in most cases, it may be possible to make an educated guess if
targeted pathogens share a common virulence strategy, such as the Type III secretion system
in Gram-negative bacteria. In other cases, identification of an inhibitor can lead to a molecu‐
lar understanding of the infection mechanism. For example, the small molecule, tachyplegi‐
nA, was found to post-translationally modify TgMLC1, a myosin light chain component, to
drive host cell penetration by the parasite T. gondii [17].
From the various studies detailed in this review, it is apparent that the library screens repre‐
sent a first step on the road of drug discovery. There has been a growing realization that
fundamental discovery of biological mechanisms oftentimes reaches a ‘valley of death’, in
which potential translation avenues into clinical therapies and diagnostics for disease treat‐
ment comes to a standstill and is lost. NIH is addressing this widening gap between basic
and clinical research with the establishment of Clinical and Translational Science Centers
across the country. The research community will have to remain pro-active to move promis‐
ing leads from the initial screen stage into downstream validation and development modes
in a timely manner. As with any drug development strategy, there still remain multiple
technical challenges that need to be overcome before small molecule inhibitors can success‐
fully transition into the clinic. Researchers will need to assess such parameters as compound
toxicity, pharmacokinetics and pharmacodynamics, and validation in animal models. How‐
ever, FDA-approved small molecule libraries can be applied to HTS as a cost-effective meth‐
od to identify existing licensed drugs for repurposing from diseases unrelated to microbial
infection. Furthermore, the development of the C. elegans whole organism model for small
molecule screening provides a novel methodology to simultaneously assess compound tox‐
icity and host response to pathogen infection. It would be informative to determine whether
small molecules identified from conventional host cell culture studies can also inhibit patho‐
gen infection in the C. elegans model. Future anti-infective treatments will most likely be
comprised of combination therapies that produce additive or synergistic effects to target key
processes in both the pathogen and the host. The overall promise of discovering novel anti-
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infective compounds has generated great hope in the biomedical community for discovery
of new countermeasures against infectious disease.
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